Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Obesity
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Obesity
    Fatty Liver Disease May Raise Heart Disease Risk in Overweight and Obese Children - (DGNews)
    Device Blocking Stomach Nerve Signals Shows Promise in Obesity - (DGNews)
    Gastric Bypass Surgery Linked to Increased Risk of Kidney Stones - (DGNews)
    TopAbstracts in Obesity 06/24/2008 - (DGNews)
    Valsartan Plus Diuretic Has More Favourable Metabolic Effects Than Diuretic-Based Regimen in Obese, Hypertensive Patients: Presented at ESH - (DGDispatch)

    News archive

     Recent webcasts/CME - Obesity
      A Case of Adolescent Obesity: The Role of Bariatric Surgery
      The Growing Problem of Childhood Obesity
      Obesity Hypoventilation Syndrome
      Effects of Physical Activity and Exercise on Reducing Risk for Cardiovascular Disease and Diabetes, with a Focus on the Obese Patient
      Strategies for Lifestyle Modification in the Prevention of Diabetes and Cardiovascular Disease

      Webcasts/CME archive

       Recent cases - Obesity
        Reconstruction of the Gastric Passage by a Side-To-Side Gastrogastrostomy After Failed Vertical-Banded Gastroplasty: A Case Report
        Perforated Appendicitis Masquerading as Acute Pancreatitis in a Morbidly Obese Patient.
        Giant Serous Cystadenoma Arising from an Accessory Ovary in a Morbidly Obese 11-Year-Old Girl: A Case Report
        Consideration of Polypharmacology in Regards to Effective Weight Reduction: A Patient on Diabetes Medication
        Consideration of Polypharmacology in Relation to Effective Weight Reduction: A Patient on Antipsychotic Medication

        Cases archive
          




        my personal edition > obesity > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Sibutramine Helps Adolescents Lose Weight: Presented at ENDO

        By Mike Fillon


        NEW ORLEANS, LA -- June 21, 2004 -- Obese teens who took the weight-loss drug sibutramine for 6 months experienced substantial weight loss without harmful side effects, according to study findings. Sibutramine is sold as Meridia in the United States.

        This new study is one of the first to show the effectiveness of drug therapy on obese adolescents, according to a report presented here on June 17th by Amelio Fernando de Godoy Matos, MD, in a clinical oral session at the 86th Annual Meeting of The Endocrine Society (ENDO). Dr. Matos is a professor in endocrinology of the Pontifical Catholic University and State Institute of Diabetes and Endocrinology in Rio de Janeiro, Brazil.

        Adolescent obesity is a health problem in both developed and developing countries. As a result, adolescents are becoming ill as a consequence of obesity and obesity-related diseases, such as diabetes and high blood pressure.

        According to Dr. Matos, until now, there has been a lack of research on drug therapy for obese adolescents, despite the lack of results in conventional treatment of obesity in this age group.

        The researchers conducted a double-blind study of 60 obese boys and girls, 14 to 18 years old with an average weight of 220 pounds, and randomized them to either sibutramine or placebo for 6 months. Both groups also participated in a controlled diet, moderate exercise and counseling.

        After 6 months, the patients taking sibutramine lost an average of 28 pounds while those taking the placebo lost only about 11 pounds. Also, more than 6 times as many adolescents taking sibutramine reduced their initial body weight by at least 10%, compared with the placebo group. In addition, 50% of the sibutramine group reduced their body weight by at least 15%, compared with none in the placebo group.

        "Patients in the sibutramine group, not only lost more weight, but they also experienced significant improvements in good cholesterol, HDL, and insulin levels," says Dr. Matos. The researchers found there were no differences in blood pressure, heart rate and echocardiography readings between the groups.

        No participants withdrew from the study due to adverse events, and the only event that occurred more frequently among the patients who took sibutramine over those who took placebo was constipation (P =.039).

        "Based on our findings, sibutramine appears to be a safe and effective treatment for obesity in adolescents," concludes Dr. Matos. "We believe larger and longer studies are needed to confirm these findings."

        Financial Support for the study was provided by Abbott Laboratories.


        [Presentation title: Treatment of Obese Adolescents with Siburtramine: A Randomized, Double-Blind, Placebo-Controlled Trial. Abstract # OR19-1]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send